Context
Non-invasive monitoring of demyelination and axonal loss in MS is crucial for prognosis and treatment but remains challenging with standard clinical MRI. Existing advanced MRI methods lack widespread pathological validation. This project aimed to develop and validate a new, clinically accessible imaging biomarker derived from conventional MRI sequences.